Testing LAD191 for moderate to severe hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate to severe hidradenitis suppurativa (HS) with at least 5 inflammatory bumps or abscesses, and you've had HS for at least 6 months.
- Your HS affects at least 2 separate areas (like both armpits), and at least one area is at stage II or III (meaning more than just a single bump).
- You have tried an antibiotic for HS that didn't work well, caused problems, or wasn't safe for you.
- You agree to use over-the-counter antiseptic washes on your HS areas every day during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This study tests an oral medicine called ritlecitinib for moderate to severe hidradenitis suppurativa (HS) in adults who haven't responded well to antibiotics. The goal is to see if it can reduce painful red lumps and improve quality of life.
This trial tests an immune-focused treatment strategy for adults with moderate-to-severe hidradenitis suppurativa (HS), especially for cases where surgery is needed. If eligible, you may get a planned study treatment and be compared to a group without HS undergoing a related surgery.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.